VCAM-targeted delivery of recombinant CD39 to the endothelium is antithrombotic, antiinflammatory and ameliorates ischaemia reperfusion injury

Nandurkar, Harshal (Primary Chief Investigator (PCI))

Australian Centre for Blood Diseases

Project: Research

Status	Finished
Effective start/end date	1/01/15 → 31/12/18

Funding

National Health & Medical Research Council (NHMRC): AUD603,813.00

Related content

Research Output

The mode of anesthesia influences outcome in mouse models of arterial thrombosis

Research output: Contribution to journal › Article › Research › peer-review